Press "Enter" to skip to content

Novartis gets European approval for sight therapy Luxturna

Luxturna is a one-time treatment for children and adults who have suffered impaired vision from an early age due to mutations in both copies of the RPE65 gene.

Original source: https://health.economictimes.indiatimes.com/news/pharma/novartis-gets-european-approval-for-sight-therapy-luxturna/66763042?utm_source=RSS&utm_medium=ETRSS

Also Read:   Swiss tap pharmaceutical reserves as coronavirus deaths rise